Ariel Isaacs, Guillermo Valenzuela Nieto, Xinghai Zhang, Naphak Modhiran, Jennifer Barr, Nazia Thakur, Yu Shang Low, Rhys H. Parry, James B. Barnes, Ronald Jara, Johanna Himelreichs, Yanfeng Yao, Camila Deride, Barbara Barthou-Gatica, Constanza Salinas-Rebolledo, Pamela Ehrenfeld, Jun Jet Hen, Noah Hayes, Devina Paramitha, Mahali S. Morgan, Christopher L. D. McMillan, Martina L. Jones, Trent P. Munro, Alexander A. Khromykh, Patrick C. Reading, Paul R. Young, Keith J. Chappell, Yi Shi, Dalan Bailey, Glenn A. Marsh, Sandra Chiu, Alejandro Rojas-Fernandez, Daniel Watterson
{"title":"A nanobody-based therapeutic targeting Nipah virus limits viral escape","authors":"Ariel Isaacs, Guillermo Valenzuela Nieto, Xinghai Zhang, Naphak Modhiran, Jennifer Barr, Nazia Thakur, Yu Shang Low, Rhys H. Parry, James B. Barnes, Ronald Jara, Johanna Himelreichs, Yanfeng Yao, Camila Deride, Barbara Barthou-Gatica, Constanza Salinas-Rebolledo, Pamela Ehrenfeld, Jun Jet Hen, Noah Hayes, Devina Paramitha, Mahali S. Morgan, Christopher L. D. McMillan, Martina L. Jones, Trent P. Munro, Alexander A. Khromykh, Patrick C. Reading, Paul R. Young, Keith J. Chappell, Yi Shi, Dalan Bailey, Glenn A. Marsh, Sandra Chiu, Alejandro Rojas-Fernandez, Daniel Watterson","doi":"10.1038/s41594-025-01598-2","DOIUrl":null,"url":null,"abstract":"<p>Nipah virus (NiV) and Hendra virus (HeV) are highly pathogenic henipaviruses without approved human vaccines or therapies. Here, we report on a highly potent bispecific therapeutic that combines an anti-fusion glycoprotein nanobody with an anti-receptor-binding glycoprotein (RBP) antibody to deliver a dual-targeting biologic that is resistant to viral escape. We show that the nanobody, DS90, engages a unique, conserved site within the fusion glycoprotein of NiV and HeV and provides neutralization and complete protection from NiV disease. Bispecific engineering of DS90 with the anti-RBP monoclonal antibody m102.4 results in neutralization, elimination of viral escape and superior protection from NiV disease compared to leading monovalent approaches. These findings carry implications for the development of cross-neutralizing immunotherapies that limit the emergence of henipaviral escape mutants.</p>","PeriodicalId":18822,"journal":{"name":"Nature structural & molecular biology","volume":"90 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature structural & molecular biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s41594-025-01598-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Nipah virus (NiV) and Hendra virus (HeV) are highly pathogenic henipaviruses without approved human vaccines or therapies. Here, we report on a highly potent bispecific therapeutic that combines an anti-fusion glycoprotein nanobody with an anti-receptor-binding glycoprotein (RBP) antibody to deliver a dual-targeting biologic that is resistant to viral escape. We show that the nanobody, DS90, engages a unique, conserved site within the fusion glycoprotein of NiV and HeV and provides neutralization and complete protection from NiV disease. Bispecific engineering of DS90 with the anti-RBP monoclonal antibody m102.4 results in neutralization, elimination of viral escape and superior protection from NiV disease compared to leading monovalent approaches. These findings carry implications for the development of cross-neutralizing immunotherapies that limit the emergence of henipaviral escape mutants.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
